CDC OKs Fourth Shot for Immunocompromised

Posted by Argentum on October 27, 2021

The CDC has updated guidance for people who are moderately to severely immunocompromised: 

Read More

Topics: Vaccine

FDA Committee Recommends Allowing Vaccine for Ages 5-11

Posted by Argentum on October 27, 2021

A U.S. Food and Drug Administration advisory committee has recommended authorization of Pfizer-BioNTech pediatric vaccine for ages 5 to 11.  

Read More

Topics: Vaccine

CDC Expands Booster Eligibility, OKs Mix and Match

Posted by Argentum on October 22, 2021

The CDC has expanded booster eligibility and its recommendations to include “mix and match” dosing—receiving a booster of a different type from the primary vaccine.  

Read More

Topics: Vaccine

FDA Authorizes ‘Mix and Match’ Boosters

Posted by Argentum on October 21, 2021

The U.S. Food and Drug Administration yesterday amended its emergency use authorizations for several actions regarding booster doses of COVID-19 vaccines, including allowing the use of heterologous, or “mix and match” booster doses: using a different type of vaccine from the primary dose for a booster dose.

Read More

Topics: Vaccine

Johnson & Johnson Booster Recommended for All 18 and Older

Posted by Argentum on October 15, 2021

An FDA independent expert panel has recommended people 18 and older have a booster shot of the Johnson & Johnson vaccine, and that it be given at least two months after the first shot. The Johnson & Johnson vaccine was given as a single dose. 

Read More

Topics: Vaccine

FDA Expert Panel Recommends Moderna Booster Dose for Those 65 and Older

Posted by Argentum on October 14, 2021

Today an FDA independent advisory panel met and voted unanimously to recommend Emergency Use Authorization (EUA) for a booster dose of the Moderna COVID-19 vaccine to be given six months after full vaccination for those 65 and older, those at high risk of severe illness due to COVID-19, and those ages 18 to 64 whose job or other settings put them at risk for complications or severe illness.

Read More

Topics: Vaccine

New Guidance: COVID-19 Booster and Flu Vaccination Considerations for Senior Living Communities

Posted by Argentum on October 1, 2021

Argentum's latest publication, COVID-19 Booster and Flu Vaccination Considerations for Senior Living Communities, gathers recent considerations regarding CDC recommendations on who should and may receive booster shots and when, as well as a list of planning and implementation considerations for flu and COVID-19 booster vaccine clinics and other vaccine administration for senior living communities.

Read More

Topics: Vaccine, Guidance

CDC Director Approves Booster Dose of Pfizer COVID-19 Vaccine for Older Adults, At-Risk Workers

Posted by Argentum on September 24, 2021

This morning, CDC Director Rochelle Walensky endorsed Pfizer COVID-19 vaccine booster shots for people 65 years of age and older and residents in long-term care settings, as well as people 18 years of age and older with underlying medical conditions. Additionally, she approved boosters for those over 18 who are at increased risk due to an occupational or institutional setting. While we are waiting for official guidance from the CDC, it should be noted that OSHA’s definition of high-risk workplaces includes those working in assisted living and continuing care retirement communities and as such, those employees could be covered under this endorsement.

Read More

Topics: Vaccine

FDA Authorizes Booster Dose of Pfizer COVID-19 Vaccine for Those 65+

Posted by Argentum on September 23, 2021

Last night, the U.S. Food and Drug Administration made an amendment to the Emergency Use Authorization (EUA) for the Pfizer COVID-19 vaccine allowing for a booster dose to be given at least six months after completion of its primary series in those 65 years of age and older. They also authorized the booster for those 18+ who are at high risk of severe COVID-19 and those whose occupations put them at risk, such as "health care workers, teachers and day care staff, grocery workers and those in homeless shelters or prisons, among others,” said acting FDA Commissioner Dr. Janet Woodcock.

Read More

Topics: Vaccine

FDA Expert Panel Recommends Pfizer Booster Dose for Those 65 and Older

Posted by Argentum on September 17, 2021

Today, the FDA’s Vaccines and Related Biological Products Advisory Committee met and voted unanimously to recommend Emergency Use Authorization (EUA) for a booster dose of the Pfizer COVID-19 vaccine to be given six months after full vaccination for those 65 and older and those at high risk of severe illness due to COVID-19. They also informally suggested that health care workers be considered for the booster dose.

Read More

Topics: Vaccine

Subscribe to Instant Email Updates

See More COVID-19 Announcements

Read more announcements related to COVID-19 on our Coronavirus Blog and access more information on:

SEE BLOG

Stay Updated on COVID-19

Find all of our latest updates on developments related to COVID-19 on our Coronavirus Toolkit.

SEE TOOLKIT